Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Company’s Milestone Achievements
August 22 2019 - 08:30AM
via NetworkWire -- Genprex Inc. (NASDAQ:GNPX) today announces
its placement in an editorial published by NetworkNewsWire ("NNW"),
a multifaceted financial news and publishing company for private
and public entities.
To view the full publication, titled “Record Revenues, Milestone
Achievements Indicate Strength, Potential of Biotech Sector,”
visit: http://nnw.fm/vn2I8.
Investing in biotech, while often an uncertain endeavor, brings
rewards far beyond the financial returns that accompany success.
Traditionally, only 10% of clinical drug trials ever make it to
market, but those that do often produce billion-dollar paydays for
parent companies. And even more satisfying for many investors is
the opportunity to be involved in a work that both saves lives and
improves the quality of life for those battling serious diseases
such as cancer.
Biotech companies such as Genprex Inc.
(NASDAQ:GNPX) are experiencing exciting growth and
reaching mile markers in their work to research and develop
life-changing options for patients. Geneprex recently outlined
significant achievements it has completed on a newly launched,
interactive corporate website timeline.
Read more at http://nnw.fm/vn2I8.
About Genprex Inc.
Genprex Inc. is a clinical stage gene therapy company developing
potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s
initial product candidate, Oncoprex™ immunogene therapy for
non-small cell lung cancer (NSCLC). Genprex’s platform technologies
are designed to administer cancer-fighting genes by encapsulating
them into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where
they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts
cell-signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. Visit the company’s web
site at www.genprex.com or follow Genprex on Twitter
at twitter.com/genprex, Facebook
at facebook.com/genprexinc and LinkedIn
at linkedin.com/company/genprex.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to reach all target markets,
industries and demographics in the most effective manner possible,
(2) article and editorial syndication to 5,000+ news outlets, (3)
enhanced press release services to ensure maximum impact, (4)
social media distribution via the Investor Brand Network (IBN) to
nearly 2 million followers, (5) a full array of corporate
communications solutions, and (6) a total news coverage solution
with NNW Prime. As a multifaceted organization with an extensive
team of contributing journalists and writers, NNW is uniquely
positioned to best serve private and public companies that desire
to reach a wide audience of investors, consumers, journalists and
the general public. By cutting through the overload of information
in today’s market, NNW brings its clients unparalleled visibility,
recognition and brand awareness. NNW is where news, content and
information converge. For more information, please visit
https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2023 to Mar 2024